来那度胺联合利妥昔单抗及地塞米松方案治疗难治复发性套细胞淋巴瘤的临床疗效观察  

Clinical effect of lenalidomide combined with rituximab and dexamethasone regimen in the treatment of refractory recurrent mantle cell lymphoma

作　　者：刘锋[1] 杜明珠[1] 高飞[1] 戴进前[1] 杨锦才 宋艳萍[1] LIU Feng;DU Mingzhu;GAO Fei;DAI Jinqian;YANG Jincai;SONG Yanping(Department of Hematology,Xi'an Central Hospital,Shaanxi Xi'an 710004,China)

机构地区：[1]西安市中心医院西安市血液病研究所,陕西西安710004

出　　处：《现代肿瘤医学》2021年第6期1020-1023,共4页Journal of Modern Oncology

基　　金：西安市科技计划项目(编号:201805095YX3SF29)。

摘　　要：目的:评价来那度胺联合利妥昔单抗及地塞米松方案治疗难治复发性套细胞淋巴瘤的临床疗效及安全性。方法:回顾性分析25例难治复发性套细胞淋巴瘤患者临床资料,所有患者均采用来那度胺联合利妥昔单抗及地塞米松方案治疗。来那度胺15 mg/(m^(2)·d),第1~21天,然后停药7天;利妥昔单抗每周375 mg/m^(2),持续4周;地塞米松10 mg/d,持续2周。28天为一个疗程,并随访至2019年3月。结果:3个疗程评估,8例获得完全缓解(CR)(32.0%),6例获得部分缓解(PR)(24.0%),7例为稳定状态(SD)(28.0%),4例为疾病进展(PD)(16.0%),总有效率为56.0%。治疗结束后总有效率达64%,25例患者1年总生存率(OS)为70%,1年无病生存率(DFS)为45%。所有患者无治疗相关死亡事件发生,毒副反应均安全可控。结论:来那度胺联合利妥昔单抗及地塞米松方案治疗难治复发性套细胞淋巴瘤患者是安全有效的,治疗相关毒副反应耐受良好,该方案可作为难治复发性套细胞淋巴瘤的挽救性治疗方案。Objective:To evaluate the clinical efficacy and safety of lenalidomide combined with rituximab and dexamethasone in the treatment of refractory recurrent mantle cell lymphoma.Methods:25 patients with refractory recurrent mantle cell lymphoma treated with lenalidomide plus rituximab and dexamethasone regimen were retrospectively analysed.Lenalidomide was 15 mg/(m^(2)·d),days 1~21,then was stopped for 7 days.Rituximab was 375 mg/m^(2) per week for 4 weeks,and dexamethasone 10 mg/d for 2 weeks,28 days for a course of treatment.All patients were followed up until March 2019.Results:After 3 courses of treatment,8 patients achieved complete remission(CR)(32.0%),6 patients with partial remission(PR)(24.0%),7 patients with stable disease(SD)(28.0%),and 4 patients with disease progression(PD)(16.0%).The total effective rate was 56.0%.The total effective rate was 64%after treatment.25 patients had a 1-year overall survival(OS)rate of 70%,and the 1-year disease-free survival(DFS)rate was 45%.No treatment-related deaths occurred in all patients.Adverse reactions were safe and controllable.Conclusion:Lenalidomide combined with rituximab and dexamethasone is safe and effective in the treatment of patients with refractory recurrent mantle cell lymphoma.The treatment-related side effects are well tolerated.This chemotherapy regimen can be used as a salvage treatment for refractory recurrent mantle cell lymphoma.

关 键 词：来那度胺 利妥昔单抗 地塞米松 套细胞淋巴瘤 难治复发 

分 类 号：R733[医药卫生—肿瘤]